ClinicalTrials.gg

Program

Ribavirin

Also written as “ribavirin”, “RBV” and “Ribavirin (RBV)”.

Its studies are mostly in Hepatitis C, Chronic · Hepatitis C · Hepatic Insufficiency · Hepatitis, Chronic · Anemia, led by 19 companies.

Furthest: phase 4, since Feb 10, 2004147 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche320 open or runningphase 4since Feb 10, 2004Feb 10, 2004none ahead
Merck310 open or runningphase 4since Sep 12, 2005Jun 13, 2002none ahead
AbbVie240 open or runningphase 3since Sep 28, 2012Feb 28, 2011none ahead
Gilead Sciences190 open or runningphase 4since Apr 29, 2014Dec 13, 2010none ahead
Vertex Pharmaceuticals110 open or runningphase 4since Nov 3, 2011Jul 27, 2004none ahead
Bristol-Myers Squibb80 open or runningphase 3since Dec 12, 2014Mar 4, 2011none ahead
Johnson & Johnson50 open or runningphase 3since Jun 19, 2008Jun 19, 2008none ahead
Tanabe Pharma40 open or runningphase 3since Nov 2, 2011Feb 24, 2008none ahead
ortho-biotech-products-l-p20 open or runningphase 2since Apr 14, 2006Apr 14, 2006none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
biolex-therapeutics-inc10 open or runningphase 2since Aug 5, 2009Aug 5, 2009none ahead
biolinerx-ltd10 open or runningphase 2since Apr 15, 2013Apr 15, 2013none ahead
fgk-clinical-research-gmbh10 open or runningphase 4since Jul 11, 2006Jul 11, 2006none ahead
getz-pharma10 open or runningphase 4since Nov 2, 2015Nov 2, 2015none ahead
icn-pharmaceuticals10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
janssen-infectious-diseases-bvba10 open or runningphase 3since Oct 28, 2010Oct 28, 2010none ahead
kawin-technology-share-holding-co-ltd10 open or runningno phasesince Feb 27, 2018Feb 27, 2018none ahead
nanogen-pharmaceutical-biotechnology-joint-stock-company10 open or runningphase 4since Apr 3, 2025Apr 3, 2025none ahead
Novartis10 open or runningphase 1since Aug 13, 2009Aug 13, 2009none ahead

Also a collaborator on its studies: toray-industries-inc, dimension-research, ppd-development-lp, integrated-therapeutics-group, roche-pharma-ag, virochem-pharma, tibotec-pharmaceutical-limited and viropharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Sep 27, 2012.

  1. Nov 18, 2015Phase 3 study in Hepatitis CAbbVie · NCT02609659 · 105 enrolled
  2. Dec 11, 2015Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02641379 · 737 enrolled · Austria
  3. Jan 28, 2016Phase 3 study in Hepatitis CBristol-Myers Squibb · NCT02673489 · 106 enrolled · United States, Canada
  4. Mar 18, 2016Phase 2 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02716779 · 68 enrolled · Germany
  5. Apr 11, 2016Phase 3 study in Hepatitis CGilead Sciences · NCT02738333 · 239 enrolled · Japan
  6. May 3, 2016Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02761629 · 180 enrolled · Brazil
  7. May 20, 2016Phase 2 study in Hepatitis CGilead Sciences · NCT02781558 · 204 enrolled · Spain
  8. May 31, 2016Phase 3 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02791256 · 23 enrolled · Belgium
  9. Jun 30, 2016Phase 3 study in Hepatitis CGilead Sciences · NCT02822794 · 117 enrolled · Japan
  10. Aug 9, 2016Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02864199 · 63 enrolled · United States, Brazil, France and more
  11. Dec 13, 2016Phase 2 study in Hepatitis CGilead Sciences · NCT02994056 · 32 enrolled · United States, France
  12. Dec 15, 2016Phase 3 study in Hepatitis CGilead Sciences · NCT02996682 · 102 enrolled · Japan
  13. Feb 27, 2018kawin-technology-share-holding-co-ltd's first study: no phase study in Hepatitis C, ChronicNew to kawin-technology-share-holding-co-ltdkawin-technology-share-holding-co-ltd · NCT03453346 · 136 enrolled · China
  14. Apr 3, 2025nanogen-pharmaceutical-biotechnology-joint-stock-company's first study: phase 4 study in Hepatitis C, ChronicNew to nanogen-pharmaceutical-biotechnology-joint-stock-companynanogen-pharmaceutical-biotechnology-joint-stock-company · NCT06922643 · 100 enrolled

TargetBeta

IMPDH1 →read by rule
“Inosine-5'-monophosphate dehydrogenase 1 inhibitor; RNA-directed RNA polymerase inhibitor; RNA inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 147 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06922643Hepatitis C, Chronic4Completednanogen-pharmaceutical-biotechnology-joint-stock-companyJan 21, 2013100
NCT03453346Hepatitis C, Chronic · China–Completedkawin-technology-share-holding-co-ltdMar 18, 2017136
NCT02996682Hepatitis C · Japan3CompletedGilead SciencesFeb 13, 2018102
NCT02994056Hepatitis C · United States, France2CompletedGilead SciencesSep 25, 201832
NCT02864199Hepatitis C, Chronic · United States, Brazil, France and more4CompletedHoffmann-La RocheSep 200763
NCT02822794Hepatitis C · Japan3CompletedGilead SciencesJun 2, 2017117
NCT02791256Hepatitis C, Chronic · Belgium3TerminatedHoffmann-La RocheJun 200823
NCT02781558Hepatitis C · Spain2CompletedGilead SciencesOct 6, 2017204
NCT02761629Hepatitis C, Chronic · Brazil4CompletedHoffmann-La RocheMay 2008180
NCT02738333Hepatitis C · Japan3CompletedGilead SciencesFeb 14, 2017239
NCT02716779Hepatitis C, Chronic · Germany2CompletedHoffmann-La RocheApr 201068
NCT02673489Hepatitis C · United States, Canada3CompletedBristol-Myers SquibbMar 2, 2017106
NCT02641379Hepatitis C, Chronic · Austria4CompletedHoffmann-La RocheNov 2013737
NCT02609659Hepatitis C3CompletedAbbVieOct 7, 2016105
NCT02600351Hepatitis C · United States, Canada, Puerto Rico3TerminatedGilead SciencesMar 21, 201787
NCT02601976Hepatitis C4Completedgetz-pharmaSep 201264
NCT02551861Hepatitis C · Canada, France2WithdrawnBristol-Myers SquibbJun 20160
NCT02493855Hepatitis C, Chronic2CompletedAbbVieApr 201646
NCT02487030Hepatitis C · Egypt3CompletedGilead SciencesNov 11, 2016255
NCT02486406Hepatitis C · United States, Belgium, Germany and more3CompletedAbbVieNov 19, 202064
NCT02472886Hepatitis C · Estonia, Russian Federation3CompletedGilead SciencesMar 30, 2016153
NCT02446717Hepatitis C, Chronic3CompletedAbbVieDec 2016141
NCT02442284Hepatitis C, Chronic3CompletedAbbVieAug 22, 201699
NCT02442271Hepatitis C, Chronic3CompletedAbbVieJul 4, 2016222
NCT02399345Hepatitis C, Chronic3CompletedAbbVieNov 201510
NCT02358044Hepatitis C3CompletedMerckNov 26, 2015257
NCT02356562Hepatitis C2CompletedAbbVieOct 28, 201629
NCT02319031Hepatitis C · Australia, France3CompletedBristol-Myers SquibbOct 201553
NCT02249182Hepatitis C · United States, Australia, New Zealand and more2CompletedGilead SciencesJun 15, 2018226
NCT02247401Hepatitis C3CompletedAbbVieAug 1, 2016160
NCT02243293Hepatitis C, Chronic3CompletedAbbVieOct 25, 2016694
NCT02220998Hepatitis C · United States, Puerto Rico3CompletedGilead SciencesJul 2015269
NCT02219477Hepatitis C, Chronic3CompletedAbbVieJun 13, 201636
NCT02201953Hepatitis C · United States, Australia, Canada and more3CompletedGilead SciencesSep 2015558
NCT02175966Hepatitis C · United States2CompletedBristol-Myers SquibbJan 28, 201535
NCT02175758Hepatitis C · United States, Australia, Belgium and more2CompletedGilead SciencesJun 21, 2018106
NCT02128542Hepatitis C · United States4CompletedGilead SciencesJun 201566
NCT02120300Chronic HCV Infection · United States2CompletedGilead SciencesAug 2015122
NCT02068222Hepatitis C, Chronic2CompletedAbbVieMar 201510
NCT02023112Hepatitis C3CompletedAbbVieApr 2015171
NCT01962441Hepatitis C · United States, Australia, Canada and more3CompletedGilead SciencesJan 7, 2015601
NCT01945294Hepatitis C, Chronic3CompletedMerckAug 5, 2015257
NCT01939197Hepatitis C3CompletedAbbVieJul 21, 2016318
NCT01938625Hepatitis C, Chronic · Germany, Poland, Spain2CompletedJohnson & JohnsonApr 27, 201535
NCT01853254Hepatitis C, Chronic · United States, Australia, Brazil and more3CompletedHoffmann-La RocheSep 2011272
NCT01852604Hepatitis C, Chronic2CompletedMerckApr 2015143
NCT01833845Hepatitis C · France2Terminatedbiolinerx-ltdApr 20144
NCT01854697Hepatitis C, Chronic3CompletedAbbVieNov 2014311
NCT01826981Hepatitis C, Chronic · New Zealand2CompletedGilead SciencesMar 2015359
NCT01833533Hepatitis C, Chronic3CompletedAbbVieDec 2013305
NCT01795911Hepatitis C · United States2CompletedBristol-Myers SquibbApr 2014165
NCT01782495Hepatitis, Chronic2CompletedAbbVieNov 2, 2016129
NCT01770223Hepatitis C4WithdrawnMerckDec 20150
NCT01753570Hepatitis C, Chronic · Japan3CompletedTanabe PharmaOct 201574
NCT01767116Hepatitis C, Chronic3CompletedAbbVieDec 2013419
NCT01715415Hepatitis C3CompletedAbbVieNov 2013395
NCT01716585Hepatitis C3CompletedAbbVieOct 2013636
NCT01704755Fibrosis3CompletedAbbVieJan 2014381
NCT01697436Healthy Volunteer · United States1CompletedHoffmann-La RocheDec 201240
NCT01701063Hepatitis C · United States, Belgium, Germany and more2TerminatedVertex PharmaceuticalsApr 201542

How it is read

Names in the registry

  • “Ribavirin”, 93 entries
  • “ribavirin”, 26 entries
  • “RBV”, 21 entries
  • “Ribavirin (RBV)”, 11 entries
  • “ribavirin [Copegus]”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.